NASDAQ:HOLX - Hologic Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $40.67 -0.57 (-1.38 %) (As of 09/25/2018 06:39 AM ET)Previous Close$41.24Today's Range$40.59 - $41.2152-Week Range$35.10 - $45.09Volume1.78 million shsAverage Volume1.85 million shsMarket Capitalization$11.22 billionP/E Ratio19.09Dividend YieldN/ABeta0.66 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health. It offers Aptima family of assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assay technologies, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test products. It also provides breast imaging and related products, and accessories comprising digital and film-based mammography systems; computer-aided detection for mammography; minimally invasive breast biopsy devices; breast biopsy site markers; and breast biopsy guidance systems. In addition, it offers Dimensions platform, a mammography gantry for 2D and tomosynthesis image acquisition and display; C-View and Intelligent 2D, a software product that provides 2D images; Selenia digital mammography platform; and SecurView Workstation. Further, it provides SculpSure, MonaLisa Touch, Vectus diode, and Cellulaze laser devices; PicoSure and Icon aesthetic systems; MedLite, RevLite, Cynergy, Elite, and SmartLipo products; and system components. Additionally, it offers NovaSure system to treat women suffering from abnormal uterine bleeding; MyoSure system for the hysteroscopic removal of fibroids; discovery and horizon X-ray bone densitometers that assess the bone density of fracture sites; and mini C-arm imaging systems to perform minimally invasive surgical procedures on a patient's extremities, such as the hand, wrist, knee, foot, and ankle. The company sells its products through direct sales and service forces, and a network of independent distributors and sales representatives. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts. Receive HOLX News and Ratings via Email Sign-up to receive the latest news and ratings for HOLX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry X-ray apparatus & tubes Sub-IndustryHealth Care Equipment SectorMedical SymbolNASDAQ:HOLX CUSIP43644010 Webwww.hologic.com Phone508-263-2900 Debt Debt-to-Equity Ratio1.12 Current Ratio1.29 Quick Ratio0.99 Price-To-Earnings Trailing P/E Ratio19.09 Forward P/E Ratio18.16 P/E Growth2.02 Sales & Book Value Annual Sales$3.06 billion Price / Sales3.62 Cash Flow$3.6151 per share Price / Cash11.25 Book Value$9.93 per share Price / Book4.10 Profitability EPS (Most Recent Fiscal Year)$2.03 Net Income$755.50 million Net Margins-2.47% Return on Equity22.18% Return on Assets7.95% Miscellaneous Employees6,233 Outstanding Shares272,120,000Market Cap$11.22 billion Hologic (NASDAQ:HOLX) Frequently Asked Questions What is Hologic's stock symbol? Hologic trades on the NASDAQ under the ticker symbol "HOLX." How were Hologic's earnings last quarter? Hologic, Inc. (NASDAQ:HOLX) posted its quarterly earnings data on Tuesday, July, 31st. The medical equipment provider reported $0.58 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.02. The medical equipment provider earned $824 million during the quarter, compared to analysts' expectations of $800.14 million. Hologic had a positive return on equity of 22.18% and a negative net margin of 2.47%. View Hologic's Earnings History. When is Hologic's next earnings date? Hologic is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for Hologic. What guidance has Hologic issued on next quarter's earnings? Hologic updated its FY18 earnings guidance on Tuesday, July, 31st. The company provided EPS guidance of $2.24-2.26 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.23. The company issued revenue guidance of $3.205-3.220 billion, compared to the consensus revenue estimate of $3.20 billion.Hologic also updated its Q4 guidance to $0.58-0.60 EPS. What price target have analysts set for HOLX? 14 equities research analysts have issued 12 month price targets for Hologic's stock. Their forecasts range from $40.00 to $50.00. On average, they expect Hologic's stock price to reach $44.5714 in the next twelve months. This suggests a possible upside of 9.6% from the stock's current price. View Analyst Price Targets for Hologic. What is the consensus analysts' recommendation for Hologic? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last year. There are currently 7 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hologic. What are Wall Street analysts saying about Hologic stock? Here are some recent quotes from research analysts about Hologic stock: 1. Needham & Company LLC analysts commented, "HOLX filed an 8-K this morning announcing it is suspending the marketing and distribution of its TempSure Vitalia handpieces and single-use probes. This is in response to an FDA public statement issued on 7/30/18 expressing concerns for vaginal rejuvenation" procedures using energy-based devices and a letter to HOLX from the FDA regarding its MonaLisa Touch laser product (we note that the letter did not mention Vitalia). The 8-K notes that HOLX had included ~$7M of revenue from Vitalia in its F4Q18 guidance or ~0.9% of our current estimate. The revenue impact could be higher than this in F4Q18 depending on how many returns of unused Vitalia products it receives, however." (8/13/2018) 2. According to Zacks Investment Research, "Hologic saw a solid third quarter of fiscal 2018. Strong international performance and improvement in the Surgical and Cynosure businesses are encouraging. Backed by a portfolio of differentiated products, the company’s Breast Health business has been going strong. We are upbeat about the company’s receipt of CE Mark for its Panther Fusion MRSA assay and Health Canada approval for its new Panther Fusion system and Panther Fusion assays. Management is looking forward to the recently-completed buyout of Faxitron Bioptics. Hologic has outperformed its industry over the past three months. However, the blood screening divestiture is likely to impede growth. Moreover, the company expects revenues from the Cynosure business to decline on a sequential basis due to seasonality and FDA-related issues pertaining to MonaLisa Touch." (8/2/2018) 3. BTIG Research analysts commented, "Raising PT to $47 from $44 After a tough F2Q, all eyes were on HOLX’s Cynosure Aesthetics business going into this F3Q. CYNO sales of $91.7M exceeded the Street’s bar of ~$88M and we think HOLX shares may enjoy a small relief rally Wednesday. We think investors will also want to see long-term growth here. The company’s core businesses remained solid, with a nice revenue beat in Breast Health and strong Blood Screening sales. We were also encouraged by what seemed like stabilization in the GYN Surgical division. Beyond these results, HOLX picked up and announced a new CFO (internal promotion) as the prior CFO moves on to Agilent. In our view, revenue guidance for F4Q set below Street estimates may have been slightly conservative, but we view this as a positive quarter overall for HOLX. We raise our PT to $47 from $44 previously, now based on 18x our 12-24 mo. adj. EPS estimate." (8/2/2018) Are investors shorting Hologic? Hologic saw a decline in short interest in August. As of August 15th, there was short interest totalling 7,190,774 shares, a decline of 18.0% from the July 31st total of 8,765,410 shares. Based on an average daily trading volume, of 3,027,886 shares, the short-interest ratio is currently 2.4 days. Approximately 2.7% of the shares of the company are sold short. View Hologic's Current Options Chain. Who are some of Hologic's key competitors? Some companies that are related to Hologic include Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), Baxter International (BAX), BEXIMCO PHARMAC/S GDR REGS (BXP), FRESENIUS SE &/S (FSNUY), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Edwards Lifesciences (EW), ESSILOR Intl S/S (ESLOY), Fresenius Medical Care AG & Co. (FMS), Align Technology (ALGN), Actelion (ALIOF), Centene (CNC), Shire (SHP) and OTSUKA HOLDINGS/ADR (OTSKY). Who are Hologic's key executives? Hologic's management team includes the folowing people: Mr. Stephen P. MacMillan, Chairman, CEO & Pres (Age 54)Mr. John M. Griffin, Gen. Counsel (Age 57)Mr. Peter J. Valenti III, Division Pres of Breast & Skeletal Health Solutions (Age 55)Mr. Eric B. Compton, Consultant (Age 53)Dr. Jay A. Stein, Co-Founder, Chairman Emeritus, CTO & Sr. VP (Age 75) Who are Hologic's major shareholders? Hologic's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.84%), Parnassus Investments CA (5.97%), Victory Capital Management Inc. (2.13%), Wells Fargo & Company MN (1.31%), Northern Trust Corp (1.25%) and Dimensional Fund Advisors LP (0.85%). Company insiders that own Hologic stock include Allison P Bebo, Benjamin Jordan Cohn, Charles J Dockendorff, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Namal Nawana, Peter J Valenti III and Sally Crawford. View Institutional Ownership Trends for Hologic. Which institutional investors are selling Hologic stock? HOLX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Wells Fargo & Company MN, Natixis, Public Employees Retirement Association of Colorado, FMR LLC, FMR LLC, Trillium Asset Management LLC and Bellevue Group AG. Company insiders that have sold Hologic company stock in the last year include Allison P Bebo, Benjamin Jordan Cohn, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Peter J Valenti III and Sally Crawford. View Insider Buying and Selling for Hologic. Which institutional investors are buying Hologic stock? HOLX stock was acquired by a variety of institutional investors in the last quarter, including Parnassus Investments CA, Mawer Investment Management Ltd., Standard Life Aberdeen plc, Gateway Investment Advisers LLC, Morgan Stanley, Partner Fund Management L.P., Victory Capital Management Inc. and Bank of Montreal Can. Company insiders that have bought Hologic stock in the last two years include Charles J Dockendorff and Namal Nawana. View Insider Buying and Selling for Hologic. How do I buy shares of Hologic? Shares of HOLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Hologic's stock price today? One share of HOLX stock can currently be purchased for approximately $40.67. How big of a company is Hologic? Hologic has a market capitalization of $11.22 billion and generates $3.06 billion in revenue each year. The medical equipment provider earns $755.50 million in net income (profit) each year or $2.03 on an earnings per share basis. Hologic employs 6,233 workers across the globe. What is Hologic's official website? The official website for Hologic is http://www.hologic.com. How can I contact Hologic? Hologic's mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-263-2900 or via email at [email protected] MarketBeat Community Rating for Hologic (NASDAQ HOLX)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 625 (Vote Outperform)Underperform Votes: 455 (Vote Underperform)Total Votes: 1,080MarketBeat's community ratings are surveys of what our community members think about Hologic and other stocks. Vote "Outperform" if you believe HOLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HOLX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/25/2018 by MarketBeat.com StaffFeatured Article: How are Outstanding Shares Different from Authorized Shares?